Avenciguat
Avenciguat[edit]
Avenciguat is a pharmaceutical compound that acts as a soluble guanylate cyclase (sGC) stimulator. It is primarily investigated for its potential therapeutic effects in treating heart failure and other cardiovascular conditions. Avenciguat is part of a class of drugs that target the nitric oxide (NO) signaling pathway, which plays a crucial role in vascular homeostasis and cardiac function.
Mechanism of Action[edit]
Avenciguat works by stimulating soluble guanylate cyclase, an enzyme that is activated by nitric oxide. This enzyme catalyzes the conversion of GTP to cyclic GMP (cGMP), a secondary messenger that mediates various physiological processes. By increasing cGMP levels, avenciguat promotes vasodilation, reduces vascular resistance, and improves cardiac output. This mechanism is particularly beneficial in conditions where nitric oxide signaling is impaired, such as in heart failure.
Clinical Development[edit]
Avenciguat is currently under investigation in clinical trials for its efficacy and safety in treating heart failure with preserved ejection fraction (HFpEF) and other cardiovascular diseases. The drug is being evaluated for its ability to improve exercise capacity, reduce symptoms, and enhance quality of life in patients with heart failure.
Potential Benefits[edit]
The potential benefits of avenciguat include:
- Improved Cardiac Function: By enhancing cGMP signaling, avenciguat may improve myocardial relaxation and reduce cardiac hypertrophy.
- Vasodilation: The drug promotes vasodilation, which can lower blood pressure and reduce the workload on the heart.
- Symptom Relief: Patients may experience relief from symptoms such as shortness of breath and fatigue.
Side Effects[edit]
As with any medication, avenciguat may cause side effects. Common side effects observed in clinical trials include headache, dizziness, and hypotension. It is important for patients to be monitored for these effects, especially when starting the medication or adjusting the dose.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
